Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study

Sylvain Garciaz, Rémy Castellano, Arnaud Jacquel, Arnaud Guille, Maxence Bourgoin, Camille Montersino, José Adélaïde, Patrick Auberger, Daniel Birnbaum, Marie Anne Hospital, Yves Collette, Norbert Vey

Blood (2024) 144 (Supplement 1): 1378.

https://doi.org/10.1182/blood-2024-207352

Published: 2024

Journal Articles

BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1

Blood (2023) 141 (10): 1209–1220.

https://doi.org/10.1182/blood.2022016943

Published: 2023

Includes: Multimedia, Supplemental data

Journal Articles

PKR-like Endoplasmic Reticulum Kinase Mediates Apoptosis Induced By Pharmacological AMP-Activated Protein Kinase Activation in Acute Myeloid Leukemia

Laury Poulain, PhD, Adrien Grenier, MD PhD, Johanna Mondesir, MD, Arnaud Jacquel, PhD, Claudie Bosc, Lucille Stuani, PhD, Rudy Birsen, MD, Sarah Mouche, Justine Decroocq, MD, Fetta Mazed, PhD, Benoit Viollet, PhD, Patrick Auberger, PhD, Pierre Sujobert, MD PhD, Didier Bouscary, MD PhD, Jean-Emmanuel Sarry, PhD, Jerome Tamburini, MD PhD

Blood (2019) 134 (Supplement_1): 2552.

https://doi.org/10.1182/blood-2019-123364

Published: 2019

Journal Articles

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Blood (2019) 134 (Supplement_1): 1355.

https://doi.org/10.1182/blood-2019-125623

Published: 2019

Journal Articles

Clonal Selection in Therapy Related Myelodysplastic Syndromes Under Azacitidine Treatment

Anne Calleja, Chimene Moreilhon, PhD, Jean Michel Karsenti, MD, Lauris Gastaud, MD, Lionel Mannone, MD, Berengere Dadone, MD, Guillaume Robert, PhD, Patrick Auberger, PhD, Sophie Raynaud, MD PhD, Thomas Cluzeau, MDPhD

Blood (2017) 130 (Supplement 1): 5297.

https://doi.org/10.1182/blood.V130.Suppl_1.5297.5297

Published: 2017

Journal Articles

Vcp-Regulated Homologous Recombination Represents a New Druggable Vulnerability in Acute Myeloid Leukemia

Lina Benajiba, Nina Fenouille, Edyta Malolepsza, Jana M Ellegast, MD, Gabriela Alexe, Yana Pikman, MD, Frédéric Luciano, Ilene Galinsky, Daniel J. DeAngelo, MD, Richard M. Stone, MD, Patrick Auberger, PhD, Josee Guirouilh-Barbat, Bernard Lopez, Mehdi Khaled, Kasper Lage, Olivier Hermine, MD PhD, Michael Hemann, Alexandre Puissant, Kimberly Stegmaier, MD

Blood (2017) 130 (Supplement 1): 880.

https://doi.org/10.1182/blood.V130.Suppl_1.880.880

Published: 2017

Journal Articles

Autophagy, a key mechanism of oncogenesis and resistance in leukemia

Patrick Auberger, Alexandre Puissant

Blood (2017) 129 (5): 547–552.

https://doi.org/10.1182/blood-2016-07-692707

Published: 2017

Journal Articles

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Alexandre Puissant, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Issam Ben-Sahra, PhD, Lina Benajiba, Gabriela Alexe, PhD, Azucena Ramos, Yana Pikman, MD, Michael R. Burgess, MD PhD, Qing Li, MD PhD, Frederic Luciano, PhD, Patrick Auberger, PhD, Ilene Galinsky, MSN, ANPc, Daniel J. DeAngelo, MD PhD, Richard M. Stone, MD, Archibald S. Perkins, MD PhD, Kevin Shannon, MD, Michael T. Hemann, PhD, Kimberly Stegmaier, MD

Blood (2016) 128 (22): 523.

https://doi.org/10.1182/blood.V128.22.523.523

Published: 2016

Journal Articles

Hemoglobin Level at Azacitidine Onset Is a Prognostic Factor of Unachievement of Three Azacitidine Cycles in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Anne Calleja, Jean Michel Karsenti, Lauris Gastaud, MD, Georges Garnier, Jean Gutnecht, Daniel Re, MD, Laurence Legros, MD PhD, Lionel Mannone, Patrick Auberger, PhD, Sophie Raynaud, MD, Thomas Cluzeau, MD PhD

Blood (2016) 128 (22): 5529.

https://doi.org/10.1182/blood.V128.22.5529.5529

Published: 2016

Journal Articles

Implication of the Anti-Apoptotic Protein Bcl-B (BCL2L10) in the Pathogenesis of Multiple Myeloma

Valentine Richez, Jr., MD, Frederic Luciano, PhD, Amine Hamouda, PhD, Alexandre Puissant, Guillaume Robert, PhD, Arnaud Jacquel, PhD, Thomas Cluzeau, MDPhD, Kenneth C Anderson, MD, Jean-Gabriel Fuzibet, MD, Patrick Auberger, PhD

Blood (2015) 126 (23): 2958.

https://doi.org/10.1182/blood.V126.23.2958.2958

Published: 2015

Journal Articles

Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Francoise Solly, MD, Catherine Koering, PhD, Aminetou mint Mohamed, PhD, Delphine Maucort-Boulch, MD, Guillaume Robert, PhD, Patrick Auberger, PhD, Pascale Flandrin-Gresta, MDPhD, Lionel Adès, MD PhD, Pierre Fenaux, MD PhD, Olivier Kosmider, MD PhD, Emmanuelle Tavernier-Tardy, MDPhD, Jérôme Cornillon, MD, Denis Guyotat, MDPhD, Lydia Campos, MD PhD, Franck Mortreux, PhD, Eric Wattel, MDPhD

Blood (2015) 126 (23): 2840.

https://doi.org/10.1182/blood.V126.23.2840.2840

Published: 2015

Journal Articles

BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Valerie Vidal, Clemence Ginet, Jean Michel Karsenti, MD, Frederic Luciano, PhD, Lauris Gastaud, MD, Georges Garnier, MD, Thorsten Braun, MD, Pierre Hirsch, MD, Emmanuel Raffoux, MD, Anne Marie Nloga, Herve Dombret, MD, Pierre-Simon Rohrlich, Lionel Ades, MD PhD, Christine Chomienne, MD PhD, Pierre Fenaux, MD PhD, Patrick Auberger, PhD, Guillaume Robert, PhD, Thomas Cluzeau, MD PhD

Blood (2014) 124 (21): 3261.

https://doi.org/10.1182/blood.V124.21.3261.3261

Published: 2014

Journal Articles

The P2Y6-AMPK Pathway Triggers Autophagy during CSF-1-Induced Human Monocyte Differentiation and Is a Potential Target in CMML

Sandrine Obba, PhDstudent, Zoheir Hizir, PhDstudent, Dorothée Selimoglu-Buet, PhD, Laurent Boyer, PhD, Anja Pfeifer, PhD, Mohamed-Amine Hamouda, PhDstudent, Diogo Goncalves, Michael Cerezo, PhDstudent, Sandrine Marchetti, PhD, Stephane Rocchi, PhD, Nathalie Droin, PhD, Guillaume Robert, PhD, Frederic Luciano, PhD, Bernard Robaye, PhD, Benoit Viollet, PhD, Laurence Legros, MD PhD, Eric Solary, MD PhD, Patrick Auberger, PhD, Arnaud Jacquel, PhD

Blood (2014) 124 (21): 4347.

https://doi.org/10.1182/blood.V124.21.4347.4347

Published: 2014

Journal Articles

PIM2 Pro-Survival Functions Are Mediated By RSK2 in AML

Marie-Anne Hospital, MD, Arnaud Jacquel, PhD, Alexa Green, Mireille Lambert, PhD, Patrick Auberger, PhD, Catherine Lacombe, Olivier Hermine, MD PhD, Ivan C Moura, PhD, Patrick Mayeux, PhD, Didier Bouscary, MD, Jerome Tamburini, MD PhD

Blood (2014) 124 (21): 912.

https://doi.org/10.1182/blood.V124.21.912.912

Published: 2014

Journal Articles

cIAPs and XIAP reduce RIPKs to silence

Arnaud Jacquel, Patrick Auberger

Blood (2014) 123 (16): 2445–2446.

https://doi.org/10.1182/blood-2014-02-555771

Published: 2014

Journal Articles

Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS)

Thomas Cluzeau, MD, PhD, Guillaume Robert, PhD, Jean Michel Karsenti, MD, Frederic Luciano, PhD, Nicolas Mounier, MD, PhD, Jill Patrice Cassuto, MD, PhD, Lionel Ades, Sophie Raynaud, MD, PhD, Pierre Fenaux, MD, PhD, Patrick Auberger, PhD

Blood (2013) 122 (21): 1568.

https://doi.org/10.1182/blood.V122.21.1568.1568

Published: 2013

Journal Articles

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia

Blood (2013) 122 (20): 3521–3532.

https://doi.org/10.1182/blood-2013-03-493163

Published: 2013

Includes: Supplemental data

Journal Articles

Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients.

Thomas Cluzeau, MD, PhD, Nicolas Mounier, MD, PhD, Valentine Richez, Jean-Michel Karsenti, MD, Faezeh Legrand, MD, PhD, Lionel Mannone, MD, Henri Vinti, MD, Laurence Legros, MD, PhD, Lauris Gastaud, Antoine Thyss, MD, Georges Garnier, MD, Daniel Re, MD, Nathalie Montagne, MD, Jean Gutnecht, MD, Patrick Auberger, MD, PhD, Sophie Raynaud, Jill-Patrice Cassuto, MD

Blood (2012) 120 (21): 2813.

https://doi.org/10.1182/blood.V120.21.2813.2813

Published: 2012

Journal Articles

Total Genomic Loss Detected by High-Density Single Nucleotide Polymorphism Array Is Predictive of Azacitidine Response in Very Poor IPSS-Revised MDS or AML Patients

Thomas Cluzeau, MD, PhD, Chimène Moreilhon, Nicolas Mounier, MD, PhD, Jean-Michel Karsenti, MD, Lionel Mannone, MD, Faezeh Legrand, MD, PhD, Valentine Richez, Lauris Gastaud, Antoine Thyss, MD, Georges Garnier, MD, Daniel Re, MD, Nathalie Montagne, MD, Jean Gutnecht, MD, Patrick Auberger, MD, PhD, Jill-Patrice Cassuto, MD, Sophie Raynaud

Blood (2012) 120 (21): 4936.

https://doi.org/10.1182/blood.V120.21.4936.4936

Published: 2012

Journal Articles

BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients

Thomas Cluzeau, MD, PhD, Guillaume Robert, Jean-Michel Karsenti, MD, Frederic Luciano, Alexandre Puissant, Faezeh Legrand, MD, PhD, Lionel Mannone, MD, Aline Renneville, MD, Claude Preudhomme, Pierre Fenaux, MD, PhD, Jill-Patrice Cassuto, MD, Sophie Raynaud, Nicolas Mounier, MD, PhD, Patrick Auberger, MD, PhD

Blood (2012) 120 (21): 701.

https://doi.org/10.1182/blood.V120.21.701.701

Published: 2012

NARROW

Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study

BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1

PKR-like Endoplasmic Reticulum Kinase Mediates Apoptosis Induced By Pharmacological AMP-Activated Protein Kinase Activation in Acute Myeloid Leukemia

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Clonal Selection in Therapy Related Myelodysplastic Syndromes Under Azacitidine Treatment

Vcp-Regulated Homologous Recombination Represents a New Druggable Vulnerability in Acute Myeloid Leukemia

Autophagy, a key mechanism of oncogenesis and resistance in leukemia

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Hemoglobin Level at Azacitidine Onset Is a Prognostic Factor of Unachievement of Three Azacitidine Cycles in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Implication of the Anti-Apoptotic Protein Bcl-B (BCL2L10) in the Pathogenesis of Multiple Myeloma

Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML)

BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

The P2Y6-AMPK Pathway Triggers Autophagy during CSF-1-Induced Human Monocyte Differentiation and Is a Potential Target in CMML

PIM2 Pro-Survival Functions Are Mediated By RSK2 in AML

cIAPs and XIAP reduce RIPKs to silence

Evaluation Of Acadesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS)

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia

Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients.

Total Genomic Loss Detected by High-Density Single Nucleotide Polymorphism Array Is Predictive of Azacitidine Response in Very Poor IPSS-Revised MDS or AML Patients

BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only